NEW YORK (GenomeWeb News) – Atreca today announced it has licensed immune repertoire capture technology from Stanford University, which the biopharmaceutical company will develop for a broad range of applications.
The technology was developed in the laboratories of William Robinson, an associate professor of medicine in the Division of Immunology and Rheumatology at Stanford, and leverages next-generation sequencing to identify new antibodies that have utility themselves and that define targets of functional immune response.
"The technology is, therefore, a highly prolific engine for the discovery and development of therapeutic antibodies, vaccines, diagnostics, and research reagents," Robinson said in a statement.
Financial and other terms of the deal were not disclosed.
Atreca, based in San Carlos, Calif., was founded in 2010. Initial investors into the firm include Mission Bay Capital.
The co-founders of the company are Lawrence Steinman, the George A. Zimmerman professor of neurology and neurological sciences and pediatrics at Stanford, and Stanford researchers Robert Axtell; Jeremy Sokolove; Yann Chong Tan; and Guy Cavet.